相关实验视频
Updated: Jun 5, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
94
PDE4D抑制剂:开启了阿尔茨海默病PET诊断的新时代
Luyang Shi1, Xue Wang1, Hongzong Si2
1College of Life Science, Qingdao University, Qingdao, China.
Neurochemistry international
|December 8, 2024
概括
针对基化酶4D (PDE4D) 的新型PET辐射追踪剂对早期阿尔茨海默氏病 (AD) 诊断具有前途. 计算机辅助药物设计有助于开发这些配体,以改善AD成像和患者治疗.
科学领域:
- 神经科学是一个神经科学.
- 放射化学 放射化学是指辐射化学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 的发病率正在增加,需要先进的诊断工具.
- 固酶 (PDE) 酶,特别是PDE4D,与AD相关的认知衰退和神经炎症有关.
- 目前阿尔茨海默病的诊断方法缺乏足够的灵敏度,无法及早发现.
研究的目的:
- 探索新型固酶4D (PDE4D) 抑制剂放射性体作为阿尔茨海默病 (AD) 的PET标记物的潜力.
- 突出计算机辅助药物设计 (CADD) 在开发阿尔茨海默氏症PET成像剂中的作用.
- 在临床前AD模型中评估PDE4D向配体的实用性.
主要方法:
- 研究了特定的PDE4D抑制剂放射连体,以确定它们与大脑中的PDE4D酶的结合亲和力.
- 利用AD动物模型来评估这些放射性链体的信号增强能力.
- 研究了计算机辅助药物设计 (CADD) 在AD药物发现和PET成像方面的应用.
主要成果:
- 作为PDE4D抑制剂的放射性链体,它们在大脑中与PDE4D酶产生特定的结合.
- 在使用这些配体的AD动物模型中观察到与病理相关的信号增强.
- 确定CADD方法对于推进AD药物设计和PET成像至关重要.
结论:
- 特定的PDE4D抑制剂放射性链体显示出作为早期阿尔茨海默病诊断的有效PET辐射追踪剂的显著潜力.
- 计算机辅助药物设计 (CADD) 对AD PET成像剂的未来发展至关重要.
- 需要通过计算机模拟进行进一步的研究,以验证及时患者干预的临床应用.
相关概念视频
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
Positron Emission Tomography
4.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.0K
![PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F57243.jpg&w=3840&q=50)
